Trial Profile

A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Auriclosene (Primary)
Indications Adenovirus infections; Infectious conjunctivitis; Viral-conjunctivitis
Focus Therapeutic Use
Acronyms BAYnovation
Sponsors NovaBay Pharmaceuticals; Stablecoin Development Corporation

Most Recent Events

23 Mar 2026 According to a Stablecoin Development Corporation media release, NovaBay Pharmaceuticals is now called Stablecoin Development Corporation.
27 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
10 Jul 2014 NovaBay Pharmaceuticals expects to report topline results of this trial by mid-August 2014.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com